Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment: Dabrafenib plus trametinib significantly increases overall response...

Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

COMy 2022: Multiple myeloma roundup

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

More from ecancer